Cancers, Vol. 16, Pages 1414: Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments

Cancers, Vol. 16, Pages 1414: Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments Cancers doi: 10.3390/cancers16071414 Authors: Eleni Kokkotou Maximilian Anagnostakis Georgios Evangelou Nikolaos K. Syrigos Ioannis Gkiozos Conventional cancer clinical trials can be time-consuming and expensive, often yielding results with limited applicability to real-world scenarios and presenting challenges for patient participation. Real-world data (RWD) studies offer a promising solution to address evidence gaps and provide essential information about the effects of cancer treatments in real-world settings. The distinction between RWD and data derived from randomized clinical trials lies in the method of data collection, as RWD by definition are obtained at the point of care. Experimental designs resembling those used in traditional clinical trials can be utilized to generate RWD, thus offering multiple benefits including increased efficiency and a more equitable balance between internal and external validity. Real-world data can be utilized in the field of pharmacovigilance to facilitate the understanding of disease progression and to formulate external control groups. By utilizing prospectively collected RWD, it is feasible to conduct pragmatic clinical trials (PCTs) that can provide evidence to support randomized study designs and extend clinical research to the patient’s point of care. To ensure the quality of real-world studies, i...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research